Altamira Therapeutics to Participate at RNA Leaders USA Congress
13 oct. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel Wickline, MD, Chief Scientific Officer, to present on the advantages of the...
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia
03 oct. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today...
Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
27 sept. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray becomes available again in selected European countries Marketing focus is on protection against airborne allergens...
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19
13 sept. 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Study has reached extended enrollment target of 160 patients Top-line data read-out expected in Q4-22 Altamira Therapeutics Ltd....
Altamira Therapeutics to Host Investor Call on September 14th
08 sept. 2022 08h57 HE
|
Altamira Therapeutics Ltd
HAMILTON, Bermuda, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today...
Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit
08 sept. 2022 07h17 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 08, 2022 (GLOBE NEWSWIRE) --Company’s Chief Scientific Officer Samuel Wickline, MD, to present on the Company’s innovative and patented OligoPhoreTM platform for the...
Altamira Therapeutics Provides Business Update
30 août 2022 09h24 HE
|
Altamira Therapeutics Ltd
Company progressing with plans to focus on its RNA businessAdvancing discussions for divestiture or spin-off of legacy assets, including BentrioTM and AM-125 nasal spraysBentrio revenues were $1.3...
Altamira Therapeutics’ CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation
03 août 2022 12h15 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Aug. 03, 2022 (GLOBE NEWSWIRE) -- Altamira’s patented RNA delivery technology platform is addressing strong need for reaching target cells outside the liver and for enhanced...
Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19
01 août 2022 08h47 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Enrollment to be continued to 160 subjects, adding 24 to ensure adequate statistical powerTop-line data read-out from trial expected in early...
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
28 juil. 2022 08h47 HE
|
Altamira Therapeutics Ltd
Independent peer-reviewed study confirms high potential for OligoPhore™ delivery platform in RNA-based treatments for osteoarthritisKnock down of JMJD3 gene remarkably mitigated severity of joint...